CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Governance Charles River Laboratories International, Inc.

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - NYSE Other stock markets 16:00:02 2026-07-02 EDT			5-day change	1st Jan Change
230.69 ^USD	+0.70%		+6.92%	+15.65%

07-01	Charles River Laboratories International Insider Sold Shares Worth $16,875,000, According to a Recent SEC Filing	MT
07-01	Argus Raises Price Target on Charles River Laboratories International to $250 From $200, Maintains Buy Rating	MT

Executive Committee: Charles River Laboratories International, Inc.

Manager

Positions heldSince

Birgit Girshick

56 year

Chief Executive Officer

2026-05-04

Glenn Coleman

58 year

Director of Finance/CFO

2026-04-05

Kerry Dailey

General Counsel

2026-03-29

Namandje Bumpus

45 year

Chief Tech/Sci/R&D Officer

2026-01-11

Mark Mintz

Chief Tech/Sci/R&D Officer

2021-01-31

Victoria Creamer

56 year

Human Resources Officer

2018-12-31

Todd Spencer

Investor Relations Contact

2018-05-31

Michael Knell

49 year

Comptroller/Controller/Auditor

2017-04-25

Matthew Daniel

Compliance Officer	2010-12-31
General Counsel	2010-12-31
Corporate Secretary	2019-12-31

Monica Lombardo

Human Resources Officer

Composition of the Board of Directors: Charles River Laboratories International, Inc.

Director

CommitteesSince

Martin MacKay

69 year

Chairman	2026-05-04
Independent Dir/Board Member	2017-07-04

Mark Enyedy

61 year

Audit Committee	2023-12-26
Governance Committee Chair	2023-12-26
Nominating Committee Chair	2023-12-26
Governance Committee	2025-05-19
Nominating Committee	2025-05-19

Virginia Wilson

71 year

Compensation Committee	2019-09-30
Audit Committee Chair
Audit Committee	2019-12-31
Governance Committee Chair

George Llado

60 year

Audit Committee
Governance Committee	2020-10-15
Nominating Committee	2020-10-15

Nancy Andrews

68 year

Governance Committee Chair	2025-05-19
Nominating Committee Chair	2025-05-19
Compensation Committee	2021-01-31

Craig Thompson

73 year

Governance Committee	2022-10-02
Compensation Committee	2022-12-04

Reshema Kemps-Polanco

53 year

Compensation Committee Chair

2025-05-19

Steven Barg

64 year

Compensation Committee

2025-05-19

Paul Graves

55 year

Audit Committee

2025-05-19

Birgit Girshick

56 year

Director/Board Member

2026-05-04

Abraham Ceesay

48 year

Director/Board Member	2025-05-19
Independent Dir/Board Member	2025-05-19

James Foster

75 year

Director/Board Member

2026-05-04

Latest Appointments: Charles River Laboratories International, Inc.

05-11	Charles River Laboratories International, Inc. Announces Board Elections	CI
02-18	Charles River Laboratories International, Inc. Announces Executive Appointments	CI
02-18	Charles River forecasts upbeat 2026 profit on improved demand for drug development services	RE
02-18	Charles River Q4 Adjusted Earnings, Revenue Decline; New CFO Named	MT
01-12	Charles River Laboratories Reports Two Planned Acquisitions; Names Namandje Bumpus as Chief Scientific and Innovation Officer	MT
01-12	Charles River Laboratories Names Dr. Namandjé N. Bumpus as Senior Vice President, Chief Scientific and Innovation Officer	CI
01-08	Charles River Laboratories International, Inc. Announces Chief Executive Officer Changes	CI

More news

Former Officers and Directors: Charles River Laboratories International, Inc.

Insider

Positions held

SinceUntil

Julie Frearson

Chief Tech/Sci/R&D Officer

2013-12-31

2026-01-11

Flavia Pease

Director of Finance/CFO	2022-04-30	2025-09-28
Corporate Officer/Principal	2022-04-24	2022-04-30

Deborah Kochevar

Director/Board Member	2008-10-28	2025-05-19
Independent Dir/Board Member	2008-10-28	2025-05-19

Richard Wallman

Director/Board Member	2011-01-23	2025-05-19
Independent Dir/Board Member	2011-01-23	2025-05-19

George Massaro

Director/Board Member	2002-12-31	2025-05-19
Independent Dir/Board Member	2002-12-31	2025-05-19

Robert Bertolini

Director/Board Member	2011-01-24	2025-05-19
Independent Dir/Board Member	2011-01-24	2025-05-19

Craig Wilson

Comptroller/Controller/Auditor

2022-12-31

2024-12-31

William Barbo

Corporate Officer/Principal	2016-09-30	2024-12-31
Sales & Marketing	2009-12-31	2016-09-30

C. Reese

Director/Board Member	2007-12-02	2024-05-07
Independent Dir/Board Member	2007-12-02	2024-05-07

Gina Mullane

Sales & Marketing

2015-12-31

2023-12-31

Barbara Patterson

Compliance Officer	2011-12-31	2023-11-30
General Counsel	2015-12-31	2023-11-30

Steven Coen

Comptroller/Controller/Auditor

2017-04-30

2023-04-30

George Milne

Director/Board Member	2001-12-31	2022-05-09
Trading-Equity	2001-12-31	2001-12-31
Independent Dir/Board Member	2001-12-31	2022-05-09

David Smith

Comptroller/Controller/Auditor	2016-10-30	2017-04-25
Director of Finance/CFO	2016-10-30	2022-04-30
Corporate Officer/Principal	2014-03-31	2016-10-30

Christine Pelletier

Human Resources Officer

2019-03-31

2021-01-31

John Kuo

Compliance Officer	2020-04-30	2020-08-31
General Counsel	2020-04-30	2020-08-31
Corporate Secretary	2020-04-30	2020-08-31

David Patrick Johst

Chief Administrative Officer	1990-12-31	2020-05-30
Human Resources Officer	2010-04-18	2011-12-14
General Counsel	2010-04-14	2020-05-30
Corporate Secretary	2009-05-03	2020-05-30

Jean-Paul Mangeolle

Director/Board Member	2018-01-14	2020-05-05
Independent Dir/Board Member	2018-01-14	2020-05-05

Shanna Cotti-Osmanski

Chief Tech/Sci/R&D Officer

2005-12-31

2019-12-31

Davide A. Molho

Chief Operating Officer	2018-02-12	2018-08-01
Corporate Officer/Principal	2009-07-02	2018-02-12
President	2018-02-12	2018-08-01

Susan E. Hardy

Investor Relations Contact

2018-05-30

Grace Lee

Human Resources Officer

2015-12-31

2017-12-31

John Crowley

Comptroller/Controller/Auditor

2013-09-29

2016-10-31

Nancy A. Gillett

Chief Tech/Sci/R&D Officer	2011-08-23	2016-03-06
Corporate Officer/Principal	1999-08-31	2011-08-23

Thomas Ackerman

Director of Finance/CFO	1995-12-31	2015-08-11
Corporate Officer/Principal	1991-12-31	1995-12-31

Arthur Hubbs

Chief Tech/Sci/R&D Officer	2010-04-30	2015-07-31
Chief Tech/Sci/R&D Officer	2019-12-31	-

Emily Hickey

Corporate Officer/Principal

2013-09-30

Samuel O. Thier

Director/Board Member	1999-12-31	2013-05-06
Independent Dir/Board Member	1999-12-31	2013-05-06

William H. Waltrip

Director/Board Member	1995-12-31	2013-05-06
Director of Research - Equity	1995-12-31	1995-12-31
Independent Dir/Board Member	1995-12-31	2013-05-06

John Ho

Corporate Officer/Principal	2011-12-31	-
Corporate Officer/Principal	2009-12-31	2009-12-31

Nancy Chang

Director/Board Member

2007-10-23

2011-01-23

Real H. Renaud

Corporate Officer/Principal

1963-12-31

2010-12-30

Cheri Walker

Corporate Officer/Principal

2007-03-31

Stephanie B. Wells

Sales & Marketing

2007-03-11

Nicholas Ventresca

Chief Tech/Sci/R&D Officer

2006-03-31

Stephen K. Durham

Corporate Officer/Principal

2011-01-03

David J. Elliott

Comptroller/Controller/Auditor

2005-09-30

Robert Cawthorn

Director/Board Member

1998-12-31

2005-02-24

S. Louise McCrary

Director/Board Member

2005-02-24

John Urquhart

Director/Board Member

2003-12-31

2004-12-31

Joanne P. Acford

General Counsel	2004-11-30	-
Corporate Secretary	2004-11-30	-

Christopher J. Perkin

Corporate Officer/Principal

2004-09-30

Linda McGoldrick

Director/Board Member

2003-12-31

Joseph C. Siglin

Corporate Officer/Principal

2011-01-03

Douglas E. Rogers

Director/Board Member	1998-12-31	2000-12-31
Director/Board Member	2009-05-03	2011-01-23

Foster Jordan

Corporate Officer/Principal

1994-01-31

Stephen D. Chubb

Director/Board Member	1993-12-31	-
Independent Dir/Board Member	1993-12-31	-

Jörg M. Geller

Corporate Officer/Principal

1985-12-31

John Montana

Corporate Officer/Principal

Kitty Sahin

Corporate Officer/Principal

Susan Desmond

Corporate Officer/Principal

Dennis R. Shaughnessy

General Counsel	-	-
Corporate Secretary	-	-

Joel McComb

Corporate Officer/Principal

John Beattie

Corporate Officer/Principal

William H. Eagan

Treasurer

2006-12-31

Thompson Dean

Director/Board Member

Walter S. Nimmo

Director/Board Member

Michael F. Ankcorn

Corporate Officer/Principal

Alastair Stuart McEwan

Corporate Officer/Principal

Karen A. Blomquist

Public Communications Contact

Andy Self

Corporate Officer/Principal

Henry L. Foster

Founder

1946-12-31

Age distribution of managers

Parity Men Women

Male	19
Female	8

Of which Executive Committee

Male	7
Female	3

Of which Directors

Male	9
Female	3

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).

Employees

19,000

Sector

Biotechnology & Medical Research

More about the company